Key result
Low-dose atorvastatin improves endothelial function versus placebo, increasing brachial artery diameter and flow velocity.
Why the study?
The effect of low-dose atorvastatin on endothelial function in normocholesterolemic type 2 diabetic patients without coronary disease was unclear.
Does atorvastatin 10 mg daily improve endothelial function in normocholesterolemic patients with type 2 diabetes mellitus without evidence of coronary disease?
RCT (n=60)
Randomly assigned
Does atorvastatin 10 mg daily improve endothelial function in normocholesterolemic patients with type 2 diabetes mellitus without evidence of coronary disease?
p-value: p=<.05
Low-dose atorvastatin improves endothelial function in patients with type 2 diabetes and normal cholesterol without coronary disease.
Supports endothelial benefits of low-dose atorvastatin in normocholesterolemic T2DM; extends RCT evidence on pleiotropic effects beyond lipids.
The authors sought to explore the effect of low-dose atorvastatin on endothelial function in normocholesterolemic patients with type 2 diabetes mellitus without evidence of coronary disease. Sixty patients with type 2 diabetes mellitus, normal serum cholesterol, and normal exercise test results were enrolled. Initial assessment was performed by measurement of the brachial artery diameter and flow velocity both at baseline and after induced hyperemia. Patients were randomly assigned to receive either atorvastatin 10 mg daily for 4 weeks (atorvastatin group=30 patients) or matched placebo for the same period (placebo group=30 patients). Follow-up assessment of the brachial artery diameter and flow velocity (both baseline and hyperemic) was performed after 4 weeks. Initially, no significant difference was found between the two groups regarding brachial artery diameter or flow velocity, both at baseline and at peak hyperemia (P>.05 for all). At follow-up, there was a significantly higher flow velocity at baseline (P<.05) and a significantly higher percent increase of brachial artery diameter (from baseline to peak hyperemia) in the atorvastatin group (P<.05). In patients with type 2 diabetes mellitus and normal serum cholesterol without evidence of coronary disease, low-dose atorvastatin improves endothelial function.
No takes yet. Share an insight, caveat, or question.
Adel et al. (2010) conducted an RCT in Type 2 diabetes mellitus (n=60). Atorvastatin vs. Placebo was evaluated on Brachial artery diameter and flow velocity at baseline and after induced hyperemia (p=<.05). Low-dose atorvastatin significantly improved endothelial function, including baseline flow velocity and percent increase in brachial artery diameter, compared to placebo (P<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: